Scott L. Friedman Joins Scholar Rock's SAB
This article was originally published in Scrip
Executive Summary
Scholar Rock, a company focused on drugs targeting growth factors in the disease microenvironment, has appointed fibrosis expert Scott L. Friedman to its scientific advisory board (SAB). Friedman is professor of medicine, dean for therapeutic discovery and chief of the division of liver diseases at the Icahn School of Medicine at Mount Sinai Hospital. He has also previously undertaken research into the underlying causes of fibrosis linked to chronic liver disease. Friedman has received various awards for his work including the China Friendship Award in 2014, the International Achievement Prize of the Europe Association for the Study of Liver Diseases in 2012 and the Hans Popper International Liver Research Prize in 2003.